Journal
FUTURE ONCOLOGY
Volume 10, Issue 16, Pages 2659-2674Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/fon.14.201
Keywords
CAF; driver mutations; EMT; HIF; hypoxia; LIMD1; NSCLC; PHD; tumor microenvironment; VHL
Categories
Funding
- Cancer Research UK (CRUK) [12733]
- Biotechnology and Biological Sciences Research Council (BBSRC) [BB/M000206/1]
- Biotechnology and Biological Sciences Research Council [BB/M000206/1, BB/L027755/1] Funding Source: researchfish
- Cancer Research UK [12733] Funding Source: researchfish
- Medical Research Council [1365502] Funding Source: researchfish
- BBSRC [BB/L027755/1, BB/M000206/1] Funding Source: UKRI
Ask authors/readers for more resources
Since the application of molecular biology in cancer biology, lung cancer research has classically focused on molecular drivers of disease. One such pathway, the hypoxic response pathway, is activated by reduced local oxygen concentrations at the tumor site. Hypoxia-driven gene and protein changes enhance epithelial-to-mesenchymal transition, remodel the extracellular matrix, drive drug resistance, support cancer stem cells and aid evasion from immune cells. However, it is not the tumor cells alone which drive this response to hypoxia, but rather their interaction with a complex milieu of supporting cells. This review will focus on recent advances in our understanding of how these cells contribute to the tumor response to hypoxia in non-small-cell lung cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available